Ipsos launches GLP-1 PersonaBot, designed to support companies’ understanding of the consumer obesity treatment market

Leveraging the framework of Ipsos PersonaBot, GLP-1 PersonaBot provides AI segment personas derived from Ipsos’ Global Consumer Obesity Monitor. Subscribers can ‘converse’ with these target segments in real-time, gaining actionable intelligence to drive informed, consumer-centric strategies.

GLP-1 PersonaBot delivers:

• Depth – – Allows engagement with five distinct AI personas representing this growing market, offering nuanced insights into attitudes, behaviors, and preferences.
• Accessibility – Designed for cross-team utilization, it allows multiple stakeholders to interact with segment personas in real-time.
• Actionability - Provides immediate, data-driven insights to inform decision-making across R&D, marketing, and product innovation.

Key applications include:

• Identifying and prioritizing high-potential segments
• Informing R&D and product positioning
• Accelerating uptake of product innovations
• Tailoring messaging and engagement strategies
• Optimizing channel mix for different consumer cohorts

GLP-1 PersonaBot from Ipsos has multiple applications for GLP-1 manufacturers, and for companies across sectors monitoring the transformative impact of new obesity medications on customer needs.

For more GLP-1 insights, please check out our latest POV: Can GLP-1s rewrite our evolutionary story?